CSPC Group
CSPC Group is a China-based pharmaceutical group focused on prescription medicines, innovative drugs, active pharmaceutical ingredients, and healthcare products.
Last updated October 9, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
CSPC Group, commonly identified in English-language corporate materials as CSPC Pharmaceutical Group, is a pharmaceutical company headquartered in Shijiazhuang, Hebei, China. Its business is organized around the research, development, manufacture, and commercialization of medicines and pharmaceutical ingredients. The group is particularly associated with prescription products in cardiovascular and cerebrovascular medicine, oncology, anti-infective therapy, central nervous system treatment, and other hospital-oriented therapeutic areas. The organization developed from a Hebei pharmaceutical manufacturing business and became a Hong Kong-listed pharmaceutical group in the late 1990s. Its historical business included large-scale production of active pharmaceutical ingredients and finished formulations, while later expansion placed greater emphasis on higher-value finished medicines, differentiated products, research and development, and international commercialization. This transition reflects a broader change in China's pharmaceutical sector from commodity-oriented bulk manufacturing toward branded generics, specialty medicines, biologics, and independently developed innovative therapies. CSPC's portfolio has included products based on butylphthalide, doxorubicin, vitamin C, antibiotics, cardiovascular medicines, and other active ingredients. Its NBP franchise, centered on butylphthalide products for ischemic stroke-related treatment, became one of the group's best-known domestic prescription-medicine businesses. CSPC has also developed and commercialized oncology products, including liposomal doxorubicin formulations, as well as a wide range of generic and specialty medicines. Product availability and regulatory status vary by market, and individual brands may be marketed through different subsidiaries or licensing arrangements. The group operates through manufacturing sites, research and development units, and commercial organizations in China, while also exporting ingredients and finished products or pursuing registrations in overseas markets. Its capabilities span chemical synthesis, formulation, active pharmaceutical ingredient production, biological or complex drug development, quality control, and pharmaceutical distribution. The group has used acquisitions, licensing, internal research, and product-line restructuring to broaden its offering and to increase the contribution of innovative and specialty products. CSPC is a public company whose shares trade in Hong Kong. It is not the same entity as similarly named Chinese pharmaceutical manufacturers or health-product businesses. Public descriptions of the company commonly distinguish its innovative-drug, generic-drug, and bulk-drug businesses, although the precise segment structure and product mix can change with annual reporting and corporate reorganization. As of the latest broadly available corporate information, CSPC remains an active China-based pharmaceutical group with a strong domestic hospital presence and an expanding focus on research-led products and international markets.
History
CSPC Group traces its corporate development to pharmaceutical manufacturing activities in Hebei and was established in its present group form in 1997. Its early business model was strongly connected with the production of pharmaceutical ingredients and finished medicines for the Chinese market. This provided manufacturing scale and technical experience, but also exposed the group to the lower margins and cyclical pricing associated with some bulk pharmaceutical products. The company became listed in Hong Kong in 1997, creating access to international capital markets and a public reporting structure. During the following years, CSPC expanded its production base and product portfolio. Its activities came to cover active pharmaceutical ingredients, chemical formulations, antibiotics, vitamins, cardiovascular medicines, and other hospital and retail products. The group used its manufacturing platform to develop both domestic branded products and export-oriented ingredient businesses. A significant later phase involved shifting the business mix toward finished medicines and differentiated therapies. Products based on butylphthalide became particularly important to the group. The NBP franchise gave CSPC a recognizable position in cerebrovascular medicine, especially in relation to ischemic stroke treatment in China. The group's oncology portfolio, including liposomal doxorubicin formulations, also supported the move toward higher-value prescription medicines. These products were developed and commercialized within a regulatory environment that increasingly rewarded quality, clinical evidence, manufacturing compliance, and differentiated therapeutic value. CSPC subsequently placed greater weight on research and development, specialty medicines, biologics or complex products, and licensing or collaboration opportunities. This strategy was consistent with the wider transformation of China's pharmaceutical industry, where companies faced generic-drug price pressure, centralized procurement, stricter quality requirements, and rising demand for innovative treatments. CSPC continued to retain a substantial generic and active-ingredient manufacturing base while seeking to reduce dependence on lower-margin commodity products. The group operates through a number of subsidiaries and manufacturing and research organizations. Its commercial reach is centered on China, where hospital procurement and prescription-drug distribution are important channels, but corporate materials also describe overseas registrations, exports, and international business activities. The exact composition of the group changes as products are launched, subsidiaries are reorganized, and regulatory approvals are obtained in different jurisdictions. CSPC remains listed in Hong Kong and continues to operate as an independent, China-based pharmaceutical group. Its current identity combines the scale of a major domestic manufacturer with a stated ambition to grow innovative and specialty medicines. Because product approvals, segment reporting, and commercial priorities change over time, the most authoritative descriptions of its present business are its annual reports, exchange filings, and official product and pipeline disclosures.
- 1997
Present group established and Hong Kong listing
[2]CSPC's present group structure dates from 1997, the same period in which the company became listed on the Hong Kong Stock Exchange.
Expansion from ingredients into finished medicines
[1]The group broadened from a manufacturing base centered on pharmaceutical ingredients into finished prescription medicines, branded generics, and specialty products.
Development of the NBP franchise
[1]Butylphthalide-based NBP products became a prominent part of CSPC's cerebrovascular-medicine portfolio.
Greater emphasis on innovative medicines
[1]CSPC increased its stated focus on research-led products, specialty medicines, complex formulations, and innovation alongside its established generic and ingredient operations.
Products and positioning
A large Chinese pharmaceutical group combining domestic prescription-drug commercialization with active pharmaceutical ingredient manufacturing, branded generics, specialty medicines, and an increasingly research-oriented innovative-drug pipeline.
Cerebrovascular medicine
NBP
NBP is CSPC's principal butylphthalide-based product franchise. It is associated with treatment of ischemic stroke and is marketed in China in multiple pharmaceutical forms. The franchise is important because it represents a move beyond commodity manufacturing into a differentiated prescription product with a recognizable therapeutic identity. Regulatory indications, formulations, and market availability should be checked against current official labeling in each jurisdiction.
Oncology medicine
Liposomal doxorubicin products
CSPC manufactures and commercializes liposomal doxorubicin products used in oncology. Liposomal delivery is intended to alter the distribution and administration characteristics of the established cytotoxic agent. This product family illustrates the group's focus on complex formulations and hospital medicines rather than only conventional small-molecule generics. Exact brands and approved indications differ by market.
Vitamin and pharmaceutical ingredient products
Vitamin C pharmaceutical products
Vitamin C has been part of CSPC's traditional pharmaceutical manufacturing and ingredient portfolio. The business includes pharmaceutical-grade material and finished products supplied through regulated medicine channels. It represents the group's historical scale in ingredient production and its continuing participation in established, high-volume pharmaceutical categories.
Anti-infective medicine
Antibiotic and anti-infective products
CSPC's broader portfolio includes antibiotic and other anti-infective medicines supplied as active ingredients and finished formulations. These products form part of the group's established manufacturing and hospital-business base. The specific products, formulations, and approvals vary across subsidiaries and markets.
Controversies
Brand decisions
- Shift toward higher-value and innovative medicinesStrategy
Background
CSPC operated in a Chinese pharmaceutical market characterized by generic-drug price competition, centralized procurement, stricter quality requirements, and increasing demand for differentiated therapies.
Action taken
The group directed greater attention to research and development, specialty medicines, complex formulations, innovative products, and the international commercialization of selected products while retaining its ingredient and generic-drug operations.
Aftermath
The strategy broadened CSPC's identity from a bulk-ingredient and conventional-medicine manufacturer toward a diversified pharmaceutical group with a larger innovation-oriented portfolio.
Recent events
Alphamab licenses KN026 rights in mainland China to CSPC subsidiary[8]
Reported:
Alphamab Biopharmaceutical announced that its wholly owned subsidiary signed an agreement with CSPC subsidiary Shanghai JMT-Bio Technology for the development and commercialization of KN026 in mainland China.
JinFang Medicine completes Series B financing[9]
Reported:
JinFang Medicine announced that it had completed a Series B financing of nearly RMB 400 million, co-led by CDH Investments and Shenzhen Capital Group's healthcare fund, with other investors participating and existing investors increasing their investment.
Junshi agrees to purchase albumin-bound paclitaxel from CSPC affiliate[10]
Reported:
Junshi entered a separate sales agreement with a CSPC subsidiary to purchase up to 27,000 vials of albumin-bound paclitaxel for use until the combination-therapy clinical trial ends; Junshi paid a purchase advance.
Junshi and CSPC terminate toripalimab combination cooperation[10]
Reported:
Junshi Biologics and CSPC terminated their cooperation on clinical development, registration and commercialization of toripalimab combined with albumin-bound paclitaxel for breast cancer, signing a termination agreement on December 30, 2019. Junshi will continue the clinical trial as the sole sponsor.
CSPC and Junshi terminate breast cancer drug collaboration[11]
Reported:
CSPC Pharmaceutical Group and Junshi agreed to terminate their agreement for the research and commercialization of a breast cancer drug, citing potential conflict with clinical research and future commercialization of another anti-PD-1 antibody under development by CSPC.
Sources11 sources
- 1CSPC Group official corporate websitee-cspc.com
- 2Hong Kong Stock Exchange equity quote for CSPC Pharmaceutical Grouphkex.com.hk
- 3CSPC Pharmaceutical Group annual reports and company announcementswww1.hkexnews.hk
- 4石药集团发展大事记e-cspc.com
- 5石药集团集团简介e-cspc.com
- 6石药集团员工故事e-cspc.com
- 7CSPC Pharmaceutical Group - Wikipediaen.wikipedia.org
- 8康宁杰瑞授权石药集团旗下公司在中国内地开发和商业化KN026prnasia.com
- 9劲方医药完成B轮融资tech.sina.com.cn
- 10君实与石药旗下附属公司另行签订紫杉醇采购协议finance.sina.com.cn
- 11石药集团与君实终止乳腺癌药物合作finance.sina.com.cn
Cite this profile: Cite the canonical profile. /brand-wiki/石药集团 · Editorial policy · How profiles are compiled